Citations (76)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Marc S. Rendell. (2021) Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetes. Expert Opinion on Pharmacotherapy 22:16, pages 2167-2179.
Read now
Read now
Celimar Sinésia, Caio Victor M. F. do Nascimento, Paulo G. S. Lacativa & Luís Maurício T. R. Lima. (2019) Physico-chemical stability of co-formulation of PEGylated human amylin with insulin. Pharmaceutical Development and Technology 24:8, pages 975-981.
Read now
Read now
Daniel A. Nadeau. (2013) Physiologic and Weight-Focused Treatment Strategies for Managing Type 2 Diabetes Mellitus: The Metformin, Glucagon-Like Peptide-1 Receptor Agonist, and Insulin (MGI) Approach. Postgraduate Medicine 125:3, pages 112-126.
Read now
Read now
Kathrin Herrmann, Juan P. Frias, Steven V. Edelman, Karen Lutz, Kevin Shan, Steven Chen, David Maggs & Orville G. Kolterman. (2013) Pramlintide Improved Measures of Glycemic Control and Body Weight in Patients With Type I Diabetes Mellitus Undergoing Continuous Subcutaneous Insulin Infusion Therapy. Postgraduate Medicine 125:3, pages 136-144.
Read now
Read now
Mohamed A AlMaatouq. (2012) Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan. Diabetes, Metabolic Syndrome and Obesity 5, pages 109-119.
Read now
Read now
Harold E Lebovitz. (2012) Pramlintide: profile of an amylin analog. Expert Review of Endocrinology & Metabolism 7:6, pages 599-609.
Read now
Read now
Caroline M Apovian. (2011) Management of diabetes across the course of disease: minimizing obesity-associated complications. Diabetes, Metabolic Syndrome and Obesity 4, pages 353-369.
Read now
Read now
Charmaine S Tam, Virgile Lecoultre & Eric Ravussin. (2011) Novel strategy for the use of leptin for obesity therapy. Expert Opinion on Biological Therapy 11:12, pages 1677-1685.
Read now
Read now
Articles from other publishers (68)
Jianjun Cao, Matthew J. Belousoff, Elliot Gerrard, Radostin Danev, Madeleine M. Fletcher, Emma Dal Maso, Herman Schreuder, Katrin Lorenz, Andreas Evers, Garima Tiwari, Melissa Besenius, Ziyu Li, Rachel M. Johnson, Denise Wootten & Patrick M. Sexton. (2023) Structural insight into selectivity of amylin and calcitonin receptor agonists. Nature Chemical Biology.
Crossref
Crossref
Karen E. Hansen, Sangita Murali, Ibrahim Z. Chaves, Garret Suen & Denise M. Ney. (2023) Glycomacropeptide Impacts Amylin-Mediated Satiety, Postprandial Markers of Glucose Homeostasis, and the Fecal Microbiome in Obese Postmenopausal Women. The Journal of Nutrition 153:7, pages 1915-1929.
Crossref
Crossref
Andrew F. Russo & Debbie L. Hay. (2023) CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiological Reviews 103:2, pages 1565-1644.
Crossref
Crossref
Benjamin Wende, Anna-Sophia Liselott Beyer, Niklas Ruhnke, Daniel Kaemmerer, Jörg Sänger, Stefan Schulz & Amelie Lupp. (2023) Expression of the Calcitonin Receptor-like Receptor (CALCRL) in Normal and Neoplastic Tissues. International Journal of Molecular Sciences 24:4, pages 3960.
Crossref
Crossref
Wenjie Ma, Hongxiang Wu, Sha Liu, Tongyao Wei, Xiang David Li, Han Liu & Xuechen Li. (2022) Chemical Synthesis of Proteins with Base‐Labile Posttranslational Modifications Enabled by a Boc‐SPPS Based General Strategy Towards Peptide C‐Terminal Salicylaldehyde Esters. Angewandte Chemie International Edition 62:1.
Crossref
Crossref
Wenjie Ma, Hongxiang Wu, Sha Liu, Tongyao Wei, Xiang David Li, Han Liu & Xuechen Li. (2022) Chemical Synthesis of Proteins with Base‐Labile Posttranslational Modifications Enabled by a Boc‐SPPS Based General Strategy Towards Peptide C‐Terminal Salicylaldehyde Esters. Angewandte Chemie 135:1.
Crossref
Crossref
Peter Kurtzhals, Søren Østergaard, Erica Nishimura & Thomas Kjeldsen. (2022) Derivatization with fatty acids in peptide and protein drug discovery. Nature Reviews Drug Discovery 22:1, pages 59-80.
Crossref
Crossref
Lei Wang, Nanxi Wang, Zhibin Yan, Zhifeng Huang & Caiyun Fu. 2023. Privileged Scaffolds in Drug Discovery. Privileged Scaffolds in Drug Discovery
795
815
.
Georgios Karamanakos, Alexander Kokkinos, Maria Dalamaga & Stavros Liatis. (2022) Highlighting the Role of Obesity and Insulin Resistance in Type 1 Diabetes and Its Associated Cardiometabolic Complications. Current Obesity Reports 11:3, pages 180-202.
Crossref
Crossref
Oscar L. Morey-Vargas, Ali Aminian, Karen Steckner, Keren Zhou, Sangeeta R. Kashyap, Derrick Cetin, Kevin M. Pantalone, Christopher Daigle, Marcio L. Griebeler, W. Scott Butsch, Robert Zimmerman, Matthew Kroh, Hussein F. Saadi, Danielle Diemer, Bartolome Burguera, Raul J. Rosenthal & M. Cecilia Lansang. (2022) Perioperative management of diabetes in patients undergoing bariatric and metabolic surgery: a narrative review and the Cleveland Clinic practical recommendations. Surgery for Obesity and Related Diseases 18:8, pages 1087-1101.
Crossref
Crossref
David S Mathiesen, Asger Lund, Jens J Holst, Filip K Knop, Thomas A Lutz & Jonatan I Bagger. (2022) THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin – physiology and pharmacology. European Journal of Endocrinology 186:6, pages R93-R111.
Crossref
Crossref
Christina N. Boyle, Yi Zheng & Thomas A. Lutz. (2022) Mediators of Amylin Action in Metabolic Control. Journal of Clinical Medicine 11:8, pages 2207.
Crossref
Crossref
Luís Maurício T. R. Lima, Talita Stelling Araújo & Marcius da Silva Almeida. (2021)
Unambiguous characterization of
PEGylation
site on human amylin by two‐dimensional nuclear magnetic resonance spectroscopy
. Peptide Science 114:2.
Crossref
Crossref
Lei Wang, Nanxi Wang, Wenping Zhang, Xurui Cheng, Zhibin Yan, Gang Shao, Xi Wang, Rui Wang & Caiyun Fu. (2022) Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Biswanath Dinda & Shekhar Saha. 2022. Natural Products in Obesity and Diabetes. Natural Products in Obesity and Diabetes
1
61
.
Daniel Fankhauser, Apostolos Alissandratos, Mantas Liutkus & Christopher J. Easton. (2021) Easy Production of “Difficult Peptides” Using Cell‐Free Protein Synthesis and a New Methionine Analogue as a Latent Peptide Cleavage Site. Chemistry – A European Journal 27:69, pages 17487-17494.
Crossref
Crossref
Lauren M. Stein, Lauren E. McGrath, Rinzin Lhamo, Kieran Koch-Laskowski, Samantha M. Fortin, Jolanta Skarbaliene, Tamara Baader-Pagler, Rasmus Just, Matthew R. Hayes & Elizabeth G. Mietlicki-Baase. (2021) The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 321:2, pages R250-R259.
Crossref
Crossref
Andrzej Fraczyk, Lukasz Janczewski, Joanna Wasko, Kamil Rozniakowski, Krystian Galecki, Zbigniew J. Kaminski & Beata Kolesinska. (2021) Non‐Aggregating Amylin Fragments as an Inhibitors of the Aggregation Process of Susceptible to Aggregation Fragments 18–22, 23–27, and 33–37 of Hormone. Chemistry & Biodiversity 18:4.
Crossref
Crossref
Hannah Louise Zakariassen, Linu Mary John & Thomas Alexander Lutz. (2020) Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases. Basic & Clinical Pharmacology & Toxicology 127:3, pages 163-177.
Crossref
Crossref
Katherine A. Kern & Elizabeth G. Mietlicki-Baase. (2020) Distributed amylin receptor signaling and its influence on motivated behavior. Physiology & Behavior 222, pages 112958.
Crossref
Crossref
Anna Thorsø Larsen, Nina Sonne, Kim Vietz Andreassen, Morten Asser Karsdal & Kim Henriksen. (2020) The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy. Journal of Pharmacology and Experimental Therapeutics 374:1, pages 74-83.
Crossref
Crossref
Anna Thorsø Larsen, Nina Sonne, Kim V. Andreassen, Morten A. Karsdal & Kim Henriksen. (2020) Dose Frequency Optimization of the Dual Amylin and Calcitonin Receptor Agonist KBP-088: Long-Lasting Improvement in Food Preference and Body Weight Loss. Journal of Pharmacology and Experimental Therapeutics 373:2, pages 269-278.
Crossref
Crossref
Zainab Riaz, Murtaza Najabat Ali, Zunaira Qureshi & Muhammad Mohsin. (2020) In Vitro Investigation and Evaluation of Novel Drug Based on Polyherbal Extract against Type 2 Diabetes. Journal of Diabetes Research 2020, pages 1-9.
Crossref
Crossref
Caio Victor M.F. Nascimento, Celimar Sinezia, Thayna Sisnande, Luís Maurício T.R. Lima & Paulo G.S. Lacativa. (2019) BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats. Peptides 114, pages 44-49.
Crossref
Crossref
Evangelia Kalaitzoglou, John L. Fowlkes, Iuliana Popescu & Kathryn M. Thrailkill. (2019) Diabetes pharmacotherapy and effects on the musculoskeletal system. Diabetes/Metabolism Research and Reviews 35:2, pages e3100.
Crossref
Crossref
Julio Rosenstock, Jan Marquard, Lori M. Laffel, Dietmar Neubacher, Stefan Kaspers, David Z. Cherney, Bernard Zinman, Jay S. Skyler, Jyothis George, Nima Soleymanlou & Bruce A. Perkins. (2018) Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care 41:12, pages 2560-2569.
Crossref
Crossref
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Rosirene Paczkowski, Jessica Jordan & Lindsey T. Murray. (2018) Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ). Journal of Patient-Reported Outcomes 2:1.
Crossref
Crossref
Elizabeth G. Mietlicki-Baase. (2018) Amylin in Alzheimer's disease: Pathological peptide or potential treatment?. Neuropharmacology 136, pages 287-297.
Crossref
Crossref
Véronique Gingras, Nadine Taleb, Amélie Roy‐Fleming, Laurent Legault & Rémi Rabasa‐Lhoret. (2017) The challenges of achieving postprandial glucose control using closed‐loop systems in patients with type 1 diabetes. Diabetes, Obesity and Metabolism 20:2, pages 245-256.
Crossref
Crossref
Renata Kowalczyk, Harveen Kaur, Antony J. Fairbanks & Margaret A. Brimble. 2018. Coupling and Decoupling of Diverse Molecular Units in Glycosciences. Coupling and Decoupling of Diverse Molecular Units in Glycosciences
1
36
.
Ewa Otto-Buczkowska & Natalia Jainta. (2017) Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?. International Journal of Endocrinology and Metabolism 16:1.
Crossref
Crossref
Sofie Gydesen, Kim Vietz AndreassenSara Toftegaard HjulerLars I. Hellgren, Morten Asser Karsdal & Kim Henriksen. (2017) Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog. American Journal of Physiology-Endocrinology and Metabolism 313:5, pages E598-E607.
Crossref
Crossref
Debbie L. Hay. (2017) Amylin. Headache: The Journal of Head and Face Pain 57, pages 89-96.
Crossref
Crossref
Abd A. Tahrani, Anthony H. Barnett & Clifford J. Bailey. (2016) Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nature Reviews Endocrinology 12:10, pages 566-592.
Crossref
Crossref
Sang-Min Lee, Debbie L. Hay & Augen A. Pioszak. (2016) Calcitonin and Amylin Receptor Peptide Interaction Mechanisms. Journal of Biological Chemistry 291:16, pages 8686-8700.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
419
458
.
Tháyna Sisnande, Luiz Henrique Guerreiro, Raquel R. Braga, Luana Jotha-Mattos, Luiza C. S. Erthal, Priscilla Tinoco, Bruno M. Ferreira & Luís Maurício T. R. Lima. (2015) Monoconjugation of Human Amylin with Methylpolyethyleneglycol. PLOS ONE 10:10, pages e0138803.
Crossref
Crossref
CJ Bailey. (2015) The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future. Clinical Pharmacology & Therapeutics 98:2, pages 170-184.
Crossref
Crossref
Debbie L. Hay, Steve Chen, Thomas A. Lutz, David G. Parkes & Jonathan D. Roth. (2015) Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacological Reviews 67:3, pages 564-600.
Crossref
Crossref
Suzanne M. Boyle, Barbara Simon & Sidney M. Kobrin. (2015) Antidiabetic Therapy in End-Stage Renal Disease. Seminars in Dialysis 28:4, pages 337-344.
Crossref
Crossref
Luc Van Gaal & André Scheen. (2015) Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment. Diabetes Care 38:6, pages 1161-1172.
Crossref
Crossref
Mohamed Raef Smaoui & Jérôme Waldispühl. (2015) Complete characterization of the mutation landscape reveals the effect on amylin stability and amyloidogenicity. Proteins: Structure, Function, and Bioinformatics 83:6, pages 1014-1026.
Crossref
Crossref
John-Olov Jansson & Vilborg Palsdottir. (2015) Brain IL-6—Where Amylin and GLP-1 Antiobesity Signaling Congregate. Diabetes 64:5, pages 1498-1499.
Crossref
Crossref
Donald Schumacher. (2013) Pharmacological Management of the Obese Patient. American Journal of Lifestyle Medicine 9:2, pages 137-156.
Crossref
Crossref
Zhi-Xu He, Zhi-Wei Zhou, Yinxue Yang, Tianxin Yang, Si-Yuan Pan, Jia-Xuan Qiu & Shu-Feng Zhou. (2015) Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:2, pages 125-138.
Crossref
Crossref
Bipasha Bose, Kishore Reddy Katikireddy & Sudheer Shenoy P. 2015. Obesity and Diabetes. Obesity and Diabetes
231
255
.
Burton E. Sobel. 2015. Coronary Artery Disease. Coronary Artery Disease
145
165
.
André J Scheen & Luc F Van Gaal. (2014) Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. The Lancet Diabetes & Endocrinology 2:11, pages 911-922.
Crossref
Crossref
Kathrin Herrmann, Kevin Shan, Steven C. Brunell & Steve Chen. (2014) Effects of Pramlintide in Patients with Type 2 Diabetes Mellitus: An Analysis Using Daily Insulin Dose Tertiles. Endocrine Practice 20:10, pages 1070-1075.
Crossref
Crossref
Elizabeth G. Mietlicki-Baase & Matthew R. Hayes. (2014) Amylin activates distributed CNS nuclei to control energy balance. Physiology & Behavior 136, pages 39-46.
Crossref
Crossref
Andrea Bortolato, Andrew S Doré, Kaspar Hollenstein, Benjamin G Tehan, Jonathan S Mason & Fiona H Marshall. (2014) Structure of Class B GPCRs: new horizons for drug discovery. British Journal of Pharmacology 171:13, pages 3132-3145.
Crossref
Crossref
Harpreet Kaur & Ruth S. Weinstock. 2014. Diabetes Mellitus and Oral Health. Diabetes Mellitus and Oral Health
69
95
.
Mingcui Zhang, Durga Pokharel & Shiyue Fang. (2014) Purification of Synthetic Peptides Using a Catching Full-Length Sequence by Polymerization Approach. Organic Letters 16:5, pages 1290-1293.
Crossref
Crossref
A D Miras & C W le Roux. (2013) Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?. International Journal of Obesity 38:3, pages 325-333.
Crossref
Crossref
Steven E Kahn, Mark E Cooper & Stefano Del Prato. (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. The Lancet 383:9922, pages 1068-1083.
Crossref
Crossref
Renata Kowalczyk, Margaret A. Brimble, Yusuke Tomabechi, Antony J. Fairbanks, Madeleine Fletcher & Debbie L. Hay. (2014) Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure–activity relationships for amylin receptor agonism. Org. Biomol. Chem. 12:41, pages 8142-8151.
Crossref
Crossref
R.C.L. Page. 2014. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions
763
787
.
Katrin Rössger, Ghislaine Charpin-El-Hamri & Martin Fussenegger. (2013) A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice. Nature Communications 4:1.
Crossref
Crossref
Denovan P. Begg & Stephen C. Woods. (2013) The endocrinology of food intake. Nature Reviews Endocrinology 9:10, pages 584-597.
Crossref
Crossref
Jichun Yang & Youfei Guan. (2013) Family with sequence similarity 3 gene family and nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 28, pages 105-111.
Crossref
Crossref
Sue D. Pedersen. (2013) Impact of Newer Medications for Type 2 Diabetes on Body Weight. Current Obesity Reports 2:2, pages 134-141.
Crossref
Crossref
Paul W. R. Harris, Renata Kowalczyk, Debbie L. Hay & Margaret A. Brimble. (2012) A Single Pseudoproline and Microwave Solid Phase Peptide Synthesis Facilitates an Efficient Synthesis of Human Amylin 1–37. International Journal of Peptide Research and Therapeutics 19:2, pages 147-155.
Crossref
Crossref
Ahmed Mehanna. (2013) Antidiabetic agents: past, present and future. Future Medicinal Chemistry 5:4, pages 411-430.
Crossref
Crossref
Colleen Flynn & George L. Bakris. (2013) Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nature Reviews Nephrology 9:3, pages 147-153.
Crossref
Crossref
Lewis Landsberg, Louis J. Aronne, Lawrence J. Beilin, Valerie Burke, Leon I. Igel, Donald Lloyd‐Jones & James Sowers. (2012) Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment. The Journal of Clinical Hypertension 15:1, pages 14-33.
Crossref
Crossref
Lewis Landsberg, Louis J. Aronne, Lawrence J. Beilin, Valerie Burke, Leon I. Igel, Donald Lloyd‐Jones & James Sowers. (2012)
Obesity‐related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the
The Obesity Society
and the
American Society of Hypertension
. Obesity 21:1, pages 8-24.
Crossref
Crossref
Jeffrey S. Freeman & Edward S. Horton. (2012) What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms. American Journal of Therapeutics 19:6, pages 449-464.
Crossref
Crossref
Leon I. Igel, Amanda G. Powell, Caroline M. Apovian & Louis J. Aronne. (2011) Advances in Medical Therapy for Weight Loss and the Weight-Centric Management of Type 2 Diabetes Mellitus. Current Atherosclerosis Reports 14:1, pages 60-69.
Crossref
Crossref